{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:17:51Z","timestamp":1777529871139,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Factor <jats:styled-content style=\"fixed-case\">XI<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">FXI<\/jats:styled-content>) concentrate is a pooled human plasma\u2010derived factor concentrate used as replacement therapy for patients with <jats:styled-content style=\"fixed-case\">FXI<\/jats:styled-content> deficiency, which provides a predictable response and consistent haemostatic cover in emergency or elective situations. It has previously been implicated in adverse events such as thrombosis and inhibitor formation, with rare case reports of fatal incidents.<\/jats:p><jats:p>We sought to establish the incidence of such complications in a retrospective case series between 1994 and 2012 at the Haemophilia Comprehensive Care Centre at Royal Free Hospital, London, <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who received <jats:styled-content style=\"fixed-case\">FXI<\/jats:styled-content> concentrate had their medical records reviewed to extract information and specific adverse events recorded such as failure of treatment with further bleeding, suspected viral transfusion transmitted infection (<jats:styled-content style=\"fixed-case\">TTI<\/jats:styled-content>), thrombosis or inhibitor formation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty\u2010six patients received 242 treatment episodes of <jats:styled-content style=\"fixed-case\">FXI<\/jats:styled-content> concentrate. Ninety percent of treatment episodes were covered with <jats:styled-content style=\"fixed-case\">BPL FXI<\/jats:styled-content> concentrate and 10% with <jats:styled-content style=\"fixed-case\">LFB<\/jats:styled-content> Hemoleven. Twelve (5%) adverse events were recorded, with eight (3.3%) of all treatment episodes were related to persistent bleeding postconcentrate infusion and there were 4 (1.7%) non\u2010bleeding adverse events. No viral <jats:styled-content style=\"fixed-case\">TTI<\/jats:styled-content>s were identified. There were two recorded inhibitors, one thrombotic event (central retinal artery occlusion) and one transfusion reaction. No patient suffering an adverse event resulted in long\u2010term morbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our experience of <jats:styled-content style=\"fixed-case\">FXI<\/jats:styled-content> concentrate use demonstrates infrequent minor adverse events related to its administration and is a safe product to use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.12868","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T20:44:24Z","timestamp":1449780264000},"page":"411-418","source":"Crossref","is-referenced-by-count":15,"title":["Safety and efficacy of factor <scp>XI<\/scp> (FXI) concentrate use in patients with <scp>FXI<\/scp> deficiency: a single\u2010centre experience of 19\u00a0years."],"prefix":"10.1111","volume":"22","author":[{"given":"G.","family":"Ling","sequence":"first","affiliation":[{"name":"Katherine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kagdi","sequence":"additional","affiliation":[{"name":"Katherine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Subel","sequence":"additional","affiliation":[{"name":"Katherine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chowdary","sequence":"additional","affiliation":[{"name":"Katherine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Katherine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01667.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12457"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92237-3"},{"key":"e_1_2_8_5_1","first-page":"1157","article-title":"Clinical experiences of a FXI concentrate: possible side\u2010effects","volume":"65","author":"Gitel S","year":"1991","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12655"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118356807.ch7"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2015.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648439"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1992.32993110761.x"},{"issue":"2","key":"e_1_2_8_11_1","first-page":"512","article-title":"Further clinical experience with a factor XI concentrate","volume":"7","author":"Dash CH","year":"2009","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2794"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103592"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110566"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830260405"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/89.3.418"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.5.1748.1748"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03044.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00385.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1661104"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01304.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01695.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13058"},{"key":"e_1_2_8_24_1","unstructured":"NHS England.Commissioning services that deliver high quality VTE prevention: guidance for commissioners. Available athttp:\/\/www.vteprevention-nhsengland.org.uk\/images\/vte-prev-guide-may2013.pdf. Accessed March 30 2015."},{"key":"e_1_2_8_25_1","first-page":"505","article-title":"A modified factor XI concentrate is safe and effective in patients with factor XI deficiency","volume":"8","author":"O'Connell N","year":"2002","journal-title":"Haemophilia"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00080.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00155.x"},{"issue":"1","key":"e_1_2_8_28_1","first-page":"13","article-title":"A decade of experience with factor XI concentrate","volume":"2","author":"Briggs N","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_8_29_1","first-page":"59","article-title":"BPL factor XI concentrate: clinical experience in the USA","volume":"3","author":"Aledort LM","year":"1997","journal-title":"Haemophilia"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12682"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1519.1519"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20214"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12868","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.12868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:57:14Z","timestamp":1693414634000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/hae.12868"],"URL":"https:\/\/doi.org\/10.1111\/hae.12868","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}